The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1614
ISSUE 1614
December 28, 2020
Ofatumumab (Kesimpta) for Multiple Sclerosis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
December 28, 2020 (Issue: 1614)
The FDA has approved a subcutaneous formulation
of the recombinant human anti-CD20 antibody
ofatumumab (Kesimpta – Novartis) for treatment
of adults with relapsing forms of multiple sclerosis
(MS), including clinically isolated syndrome (initial
neurological episode), relapsing-remitting disease,
and active secondary progressive MS (SPMS).
Kesimpta is the second anti-CD20 antibody to be
approved for these indications; IV ocrelizumab
(Ocrevus), which is also approved for treatment
of primary progressive MS, was the first. An IV
formulation of ofatumumab (Arzerra) has been
available for treatment of chronic lymphocytic
leukemia (CLL) since 2010.
... more
- Ocrelizumab (Ocrevus) for MS. Med Lett Drugs Ther 2017; 59:98.
- Ofatumumab (Arzerra) for CLL. Med Lett Drugs Ther 2010; 52:51.
- Drugs for multiple sclerosis. Med Lett Drugs Ther 2016; 58:71.
- S Faissner and R Gold. Progressive multiple sclerosis: latest therapeutic developments and future directions. Ther Adv Neurol Disord 2019; 12:1.
- F Sellebjerg et al. Anti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis. CNS Drugs 2020; 34:269.
- SL Hauser et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med 2020; 383:546.
- D Baker et al. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol 2020; 202:149.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Ofatumumab (Kesimpta) for Multiple Sclerosis
Article code: 1614c
Electronic, downloadable article - $45
Article code: 1614c
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian